Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Prior treatment

• Self-reported change in body weight \> 5 kg within 90 days before screening.
• History of chronic pancreatitis or history of acute pancreatitis within 180 days before screening.

Other illness

• Type 1 or Typ2 diabetes mellitus.
• Obesity induced by other endocrinologic disorders.
• Family (first-degree relative\[s\]) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2.
• History of unstable major depressive disorder (MDD) or other severe psychiatric disorder within 2 years before screening.
• Lifetime history of suicide attempt.

• Age ≥ 18 years.
• Body mass index ≥ 30 kg/m2 or ≥27 kg/m² to \< 30 kg/m2 with at least 1 of the following weight-related comorbidities: hypertension, dyslipidemia, history of obstructive sleep apnea, history of cardiovascular disease, history of metabolic dysfunction-associated steatotic liver disease (MASLD) or Metabolic Dysfunction-Associated Steatohepatitis (MASH).
• History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.